Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

NCT01332656 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG: Ombrabulin (AVE8062)
DRUG: Placebo
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Sanofi